K-ras mutations and cetuximab in colorectal cancer [7]

New England Journal of Medicine

Volumn 360, Issue 8, 2009, Pages 834-

  De Roock, Wendy ^a   Lambrechts, Diether ^b   Tejpar, Sabine ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; MONOCLONAL ANTIBODY;

COLORECTAL TUMOR; GENETICS; HUMAN; MUTATION; NOTE; ONCOGENE RAS; CODON; DISEASE COURSE; MORTALITY; SEQUENCE HOMOLOGY; SURVIVAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; GENES, RAS; HUMANS; MUTATION; CODON; DISEASE PROGRESSION; SEQUENCE HOMOLOGY, NUCLEIC ACID; SURVIVAL ANALYSIS;

EID: 61449258442     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (2)

1. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508-15. (Pubitemid 351325672)
2. Di Nicolantonio F, Martini M, Molinari F, et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008;26:5705-12.